Psoriatic Arthritis
From the Journals
Financial incentives affect the adoption of biosimilars
Adoption of infliximab biosimilars proceeded more slowly at an academic medical center than at a neighboring VAMC, where financial incentives to...
Feature
‘We’re in great distress here,’ infusion center CMO says
Thrivewell is also deploying a mobile infusion unit to recovered COVID-19 patients who require an infusion for their autoimmune disease.
From the Journals
JAK inhibitors may increase risk of herpes zoster
Patients who received Janus kinase (JAK) inhibitors had a 57% increased relative risk of herpes zoster infection.
From the Journals
Genome study examines heritability of psoriatic disease subtypes
Cutaneous psoriasis shows a greater contribution from genetic variants than does psoriatic arthritis or psoriasis vulgaris.
From the Journals
Rapid shift to adalimumab biosimilars in Denmark contrasts with U.S. experience
The Danish health care system’s shift to adalimumab biosimilars led to substantial decreases in cost.
Multimedia
Psoriasis Therapy During the COVID-19 Pandemic: Should Patients Continue Biologics?
Latest News
AAD-NPF releases first guidelines for nonbiologic treatments of psoriasis
Guidelines for nonbiologic systemic agents for psoriasis provide strong evidence for use of apremilast and guidance for off-label drugs.
From the Journals
HLA-B27 status predicts radiographic phenotype of axSpA
Study findings from ankylosing spondylitis and axial psoriatic arthritis patients emphasize “the importance of HLA-B27 status in severity and the...
Conference Coverage
Meta-analysis highlights safety concerns with interleukin inhibition
MAUI, HAWAII – Increased risks seen for serious infections, cancer, and opportunistic infections.
Guidelines
New guideline offers recommendations for reproductive health in patients with rheumatic diseases
Among its many recommendations, the guideline strongly advises that women with RMD considering pregnancy switch to pregnancy‐compatible medication...
Conference Coverage
Secukinumab outperforms adalimumab overall for PsA
MAUI, HAWAII – Results of the 52-week, head-to-head EXCEED study.